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RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL
ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME,
AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN
PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
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The American Urological Association (AUA) symptom index is both valid and reliable in identifying the
need to treat patients with benign prostatic hyperplasia (BPH) and in monitoring their response to therapy.
We evaluated the relationships between AUA symptom index, disease-specific quality of life question,
and prostate volume in patients with BPH. A total of 100 patients who came to Kaohsiung Medical University
Hospital, Taiwan, for help due to lower urinary tract symptoms (LUTS) and who were diagnosed with
BPH between October 2002 and June 2003 were included in the study. All patients were evaluated using
transrectal ultrasonography, AUA symptom index, and disease-specific quality of life question. The disease-
specific quality of life question showed good correlation with AUA symptom score (r = 0.815, p < 0.01),
but weak correlation with prostate volume (r = 0.225, p < 0.05) and age (r = 0.274, p < 0.05). Prostate volume
had weak correlation with AUA symptom score (r = 0.251, p < 0.05) and age (r = 0.472, p < 0.01), but
good correlation with prostate specific antigen (r = 0.638, p < 0.01). In addition to AUA symptom index,
we suggest using the disease-specific quality of life question to evaluate the influence on quality of life
and response to treatment in clinical practice. Moreover, we should assess the impact of BPH symptoms
rather than the increase in prostate volume during the management of BPH.
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Benign prostatic hyperplasia (BPH) has a high prevalence
in the male population that increases with age [1,2]. It often
produces chronic and progressive lower urinary tract
symptoms (LUTS) or chronic complications, leading many
men to seek treatment [2,3]. The American Urological Asso-
ciation (AUA) symptom index is now widely used to as-
sess patients with suspected BPH. It consists of a series
of seven questions that address obstructive and irritative
voiding symptoms [4]. The index has been shown to be
clinically sensible, reliable, valid, and reproducible [4,5].
The AUA symptom index has been adopted by the World
Health Organization (WHO) as the International Prostate
Symptom Score (IPSS) after the addition of one disease-
specific quality of life question as a means of assessing the
global impact of BPH on quality of life [6]. The aim of this
study was to evaluate the relationships between AUA symp-
tom index, the disease-specific quality of life question, and
prostate volume in patients who came to our hospital for
LUTS suggestive of BPH.
PATIENTS AND METHODS
Patients who came to Kaohsiung Medical University Hos-
pital, Taiwan, between October 2002 and June 2003 com-
plaining of LUTS suggestive of BPH were included in
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this study. No patients had received medication for BPH
in the previous month. Patients who had a history of neuro-
genic disease, urethral stricture, or bladder tumor that
would interfere with micturition, or who came for help with
an indwelling catheter due to urine retention, were excluded
from the study. Patients who had concomitant urinary tract
infection (UTI) or distal ureter stone were also excluded.
During evaluations, any patient with an abnormal digital
rectal examination or elevated serum prostate specific anti-
gen (PSA) level (> 4 ng/mL) was asked to undergo prostate
biopsy to exclude prostate cancer. If prostate cancer was
found, the patient was excluded.
The evaluations included AUA symptom index, the
disease-specific quality of life question (bother score), digital
rectal examination, transrectal ultrasonography (7-MHz
8551 Probe, 2001 Medical Ultrasound Scanner; B-K Medical
A/S, Herlev, Denmark), serum PSA (Immulite 2000 PSA
assay; Diagnostic Products Corp, Los Angeles, CA, USA),
and urinalysis. Prostate volume was calculated using the
prostate ellipsoid formula: (pi/6) × (anterior–posterior
diameter) × (transverse diameter) × (sagittal diameter).
The AUA symptom index includes seven items to eva-
luate LUTS (incomplete emptying, frequency, intermit-
tency, urgency, weak stream, hesitancy, and nocturia),
with the score of each item ranging from 0 to 5 points. The
total symptom score was obtained by adding the seven
scores (range, 0 to 35 points), and was categorized as mild
(≤ 7), moderate (8–19), or severe (≥ 20). For symptomatic
classification, we divided the symptom score into an ob-
structive subscore (sum of scores for questions 1, 3, 5, and
6) and an irritative subscore (sum of scores for questions
2, 4, and 7). The disease-specific quality of life question
was phrased as follows: “If you were to spend the rest of
your life with your urinary condition just the way it is now,
how would you feel about that?”, and the answering scale
ranged from 0 (delighted) to 6 (terrible). The AUA symptom
index questions and the disease-specific quality of life
question were administered to all patients with instruc-
tion from doctors.
Results are expressed as mean ±  standard deviation,
unless otherwise indicated. Pearson’s correlation coefficient
is used to express the strength of the correlations between
age, prostate volume, PSA level, AUA symptom score,
obstructive subscore, irritative subscore, and bother score.
Data were considered significant if p was less than 0.05.
Statistical differences between mild, moderate, and severe
symptom groups were compared using the ANOVA pro-
cedure. A p value of less than 0.05 was considered statis-
tically significant.
RESULTS
From October 2002 to June 2003, 107 patients came to our
hospital for help due to LUTS suggestive of BPH. Seven
patients were excluded from this study, five for concomi-
tant UTI, one for concomitant bladder tumor, and one for
prostate cancer that was confirmed by prostate biopsy ini-
tiated for an elevated PSA level. A total of 100 patients
were included in the study.
The mean age was 59.6 ± 10.66 years (median, 59 years;
range, 40–90 years). The mean prostate volume was 34.89 ±
16.40 mL (median, 29.6 mL; range, 20.0–120 mL). The mean
total AUA symptom score was 11.54 ±  6.84 (median, 11;
range, 1–33), the mean obstructive subscore was 6.38 ± 4.67
(median, 6; range, 0–20), and the mean irritative subscore
was 5.16 ± 2.99 (median, 5; range, 0–13). The mean bother
score was 3.37 ± 1.36 (median, 4; range, 0–6). The mean PSA
level was 2.71 ± 4.79 ng/mL (median, 0.995 ng/mL; range,
0.12–11.90 ng/mL).
The correlations between age, prostate volume, PSA
level, AUA symptom score, obstructive subscore, irritative
subscore, and bother score are shown in Table 1.
All patients were divided into groups according to total
AUA symptom score: mild (n = 31), moderate (n = 58), and
severe (n = 11). There was a statistically significant difference
in age among the three groups (p = 0.02), with a greater
mean age in the severe symptom group. However, there
was no statistically significant difference in prostate volume
and PSA level among the three groups (Table 2).
DISCUSSION
BPH is a common condition among older men, resulting in
chronic LUTS that are bothersome, impair physiologic and
functional well-being, and interfere with activities of daily
living [7,8]. The main reasons for patients to seek treatment
for BPH are subjective symptoms, feeling bothered, and
negative impact on quality of life [2,3].
The AUA symptom index is a seven-item scale developed
by a multidisciplinary measurement committee of the AUA,
and is primarily intended for use as an evaluative measure
for BPH [4]. The validity (the extent to which a tool measures
what it is supposed to measure), reproducibility (the extent
to which a tool gives consistent results in stable individuals
over time), and responsiveness (the ability to detect clinical
change) of the AUA symptom index have been well docu-
mented by several studies [4,9–13].
The AUA symptom index is both valid and reliable in
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identifying the need to treat patients and in monitoring
their response to therapy [4]. The AUA practice guidelines
committee recommends that the AUA symptom index
should be used as the symptom-scoring instrument in the
initial assessment of each patient presenting with BPH.
The extent of further evaluation and treatment is sug-
gested according to whether symptoms are mild (0–7),
moderate (8–19), or severe (20–35) [14].
However, the AUA symptom index has also received
considerable criticism because it is unable to discriminate
BPH from other types of voiding dysfunction in either male
or female patients [6,15,16], to differentiate obstructed from
non-obstructed BPH [17–19], or to differentiate either form
of BPH from detrusor hyperreflexia [19,20].
It is critical to assess symptoms and quality of life from
a patient’s perspective when deciding BPH treatment. The
condition-specific impact score is much more sensitive to
differences in symptoms than general measures of quality
of life.
The WHO International Consultation on BPH has
recommended the use of the AUA symptom index and a
single disease-specific quality of life question that asks
patients to assess their feelings about their symptoms for
studies of BPH treatment. The disease-specific quality of life
question is a good single item for assessing the quality of life
and treatment outcome, and is more readily interpretable
on an individual clinical basis than a numeric index [11].
The symptoms of BPH can be divided into obstructive
Table 1. Relationship among different variables by Pearson’s correlation coefficient
Age Prostate volume PSA Total score Obstructive subscore Irritative subscore
Age r
p
Prostate volume r 0.472*
p < 0.001
PSA r 0.420* 0.638*
p < 0.001 < 0.001
Total score r 0.252† 0.251† 0.095
p 0.011 0.012 0.346
Obstructive subscore r 0.218† 0.221† 0.052 0.933*
p 0.029 0.027 0.605 < 0.001
Irritative subscore r 0.236† 0.230† 0.136 0.828* 0.571*
p 0.018 0.022 0.177 < 0.001 < 0.001
Bother score r 0.274* 0.229† 0.077 0.815* 0.763* 0.672*
p 0.006 0.022 0.446 < 0.001 < 0.001 < 0.001
*p < 0.01; †p < 0.05. PSA = serum prostate specific antigen; Bother score = disease-specific quality of life question.
Table 2. Characteristics of the three symptom groups
Mild (0–7), n = 31 Moderate (8–19), n = 58 Severe (20–35), n = 11 p
Age, yr 57.80 ±  10.60 59.03 ±  10.5 67.63 ±  8.54 0.02
Prostate volume, cm3 30.71 ±  12.25 36.04 ±  18.4 40.56 ±  13.81 0.16
PSA, ng/mL 2.70 ±  6.08 2.28 ±  3.25 4.99 ±  6.98 0.23
Total AUA score 3.90 ±  1.94 13.29 ±  3.57 23.81 ±  3.79
Obstructive subscore 1.52 ±  1.87 7.47 ±  2.90 14.36 ±  3.20 < 0.01
Irritative subscore 2.39 ±  1.52 5.83 ±  2.26 9.45 ±  2.46 < 0.01
Bother score 1.97 ±  0.91 3.79 ±  0.91 5.09 ±  0.83 < 0.01
PSA = serum prostate specific antigen; AUA = American Urological Association.
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and irritative complaints. Obstructive symptoms result
from mechanical and dynamic obstruction, but irritative
symptoms result from the secondary response of the blad-
der to the increased outlet resistance. As prostatic enlarge-
ment occurs, mechanical obstruction may result from intru-
sion into the urethral lumen or bladder neck, leading to a
higher bladder outlet resistance. The prostate stroma is rich
in adrenergic nerve supply, so the tone of the prostatic ure-
thra may increase, creating dynamic obstruction when the
prostate grows. In our study, we tried to divide the AUA
symptom score into obstructive and irritative subscores, to
observe which symptoms have better correlation with the
bother score. The obstructive subscore (r = 0.763, p < 0.001)
had better correlation than the irritative subscore (r = 0.673,
p < 0.001). It seems that patients may care more about
obstructive symptoms than irritative symptoms. Further
studies may be needed to confirm this.
We also found that the bother score had good correlation
with the AUA symptom score (r = 0.815, p < 0.01), but weak
correlation with prostate volume (r = 0.225, p < 0.05) and age
(r = 0.274, p < 0.05). Prostate volume was weakly correlated
with the AUA symptom score (r = 0.251, p < 0.05) and age
(r = 0.472, p < 0.01), but had good correlation with PSA lev-
el (r = 0.638, p < 0.01). The results were similar to those
obtained by Bosch et al in 1995 [6], who found good cor-
relation between AUA symptom score and bother score
(r = 0.74, p = 0.001), but weak correlation between AUA
symptom score and total prostate volume (r = 0.19, p <
0.001) and age (r = 0.09, p = 0.04).
The lack of relationship between prostate volume and
symptoms may be due to variable patterns of prostatic
enlargement. Excess growth in the transitional zone can
produce enlargement without significant obstructive
symptoms. Such growth was reported in an autopsy study
[21]. On the other hand, periurethral enlargement or nodu-
lar growth can produce obstructive symptoms with no
great enlargement of the gland as a whole [22].
We also divided patients into three groups according to
their AUA symptom scores. No statistically significant
differences in prostate volume and PSA level were found
among the three groups. However, there was a statistically
significant difference in age (p = 0.02); patients in the severe
symptom group were older. Chute et al found that incom-
plete emptying, intermittency, urgency, weak stream, and
nocturia were strongly age-related [1]. Kojima et al found
similar results [23]. Therefore, aging may also play an im-
portant role in the development of LUTS.
Although Garraway et al adopted prostate weight
(≥ 20 g) as the criterion for BPH [24], some studies preferred
the presumed circle area ratio [23,25]. Presumed circle area
ratio is the ratio of the area of maximum prostatic section to
the area of a presumed circle having the same circumference
as that of the section. It is based on the idea that the degree
of obstruction in BPH can be evaluated by estimating how
closely a horizontal section of the entire prostate approaches
a circle on transrectal sonography [23]. Kojima et al found
a stronger correlation between presumed circle area ratio
and symptom score (r = 0.150, p < 0.0001) than between
prostate volume and symptom score (r = 0.072, p < 0.0001)
using simple regression analysis, so they suggested that
presumed circle area ratio was preferable to prostate vol-
ume in representing the degree of BPH in terms of the
severity of urinary symptoms [23]. Further studies are
needed to evaluate whether the appearance or size of the
prostate plays an important role in the development of uri-
nary symptoms.
In conclusion, it is critical to assess symptoms and
quality of life from a patient’s perspective in assessing
BPH treatment. In addition to the AUA symptom index, we
suggest using the disease-specific quality of life question to
evaluate the influence of symptoms on quality of life and
response to treatment in clinical practice, as recommended
by the WHO International Consultation on BPH. We found
that the disease-specific quality of life question showed
good correlation with the AUA symptom score, but neither
AUA symptom score nor the disease-specific quality of life
question had good correlation with prostate volume.
Therefore, we should focus on the impact of BPH symp-
toms, rather than the increase in prostate volume, during
the management of BPH.
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